Skip to content

Serotonin: all studies

Page 41 of 400: studies 401 to 410 of 3,999, newest first. Back to the serotonin overview

Research

A Complex Impact of Systemically Administered 5-HT2A Receptor Ligands on Conditioned Fear

The International Journal of Neuropsychopharmacology July 5, 2021 Sven Melker Hagsäter, Robert Pettersson, Christopher Pettersson et al. 29 citations

Abstract Background Though drugs binding to serotonergic 5-HT2A receptors have long been claimed to influence human anxiety, it remains unclear if this receptor subtype is best described as anxiety promoting or anxiety dampening. Whereas conditioned fear expressed as freezing in rats is modified by application of 5-HT2A–acting drugs locally into different brain regions, reports on the effect of...

How do serotonergic psychedelics treat depression: The potential role of neuroplasticity

World Journal of Psychiatry June 19, 2021 Hewa Artin, S. Zisook, Dhakshin Ramanathan

Depression is a common mental disorder and one of the leading causes of disability around the world. Monoaminergic antidepressants often take weeks to months to work and are not effective for all patients. This has led to a search for a better understanding of the pathogenesis of depression as well as to the development of novel antidepressants. One such novel antidepressant is ketamine, which...

New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review.

Experimental Neurology May 1, 2021 Fabrizio Schifano, Stefania Chiappini, Andrea Miuli et al. 49 citations

The use of several new psychoactive substances (NPS) has become very popular and is posing global health risks. Chemically and pharmacologically diverse molecules are constantly emerging and are presenting with a wide range of clinical implications. Serotonin toxicity, and specifically Serotonin Syndrome (SS), might develop as a result of an over-activation of the serotoninergic system caused...

DOI: 10.1016/j.expneurol.2021.113638 (opens in new tab) Full text (opens in new tab) Bupropion New psychoactive substances Phenethylamines Serotonin syndrome +4

Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice

Proceedings of the National Academy of Sciences April 13, 2021 Natalie Hesselgrave, Timothy A. Troppoli, Andreas B. Wulff et al. 380 citations

Significance Psychedelic compounds, such as psilocybin, have beneficial actions in several psychiatric diseases. They also produce strong alterations of consciousness, which may be a barrier to their widespread use. We found that psilocybin has fast-acting antidepressant-like properties in mice. Using multiple assays of hedonic behavior and an antagonist of prohallucinatory 5-HT2A receptors, we...

Tropane-Based Ibogaine Analog Rescues Folding-Deficient Serotonin and Dopamine Transporters.

ACS Pharmacology & Translational Science April 9, 2021 Shreyas Bhat, Daryl A. Guthrie, Ameya Kasture et al. 37 citations

Missense mutations that give rise to protein misfolding are rare, but collectively, defective protein folding diseases are consequential. Folding deficiencies are amenable to pharmacological correction (pharmacochaperoning), but the underlying mechanisms remain enigmatic. Ibogaine and its active metabolite noribogaine correct folding defects in the dopamine transporter (DAT), but they rescue...

DOI: 10.1021/acsptsci.0c00102 (opens in new tab) Full text (opens in new tab) Protein misfolding Protein folding diseases Proteinopathy Proteostasis +15

Lysergic acid diethylamide (LSD) promotes social behaviour through 5-HT 2A and ampa in the medial prefrontal cortex (MPFC)

European Psychiatry April 1, 2021 Athanasios Markopoulos, Antonio Inserra, Danilo de Gregorio et al. 5 citations

Introduction Autism Spectrum Disorder and Social Anxiety Disorder are mental illnesses characterized by a dysfunction in social behavior (SB); a phenomenon largely mediated by the medial prefrontal cortex (mPFC). Clinical studies have demonstrated that lysergic acid diethylamide (LSD), a partial agonist of the 5-HT 2A receptor, can promote SB. However, its mechanism of action on SB is unknown....

Methylenedioxymethamphetamine (MDMA): Serotonergic and dopaminergic mechanisms related to its use and misuse

Journal of Neurochemistry March 12, 2021 Susan Schenk, Quenten Highgate 47 citations

Abstract Methylenedioxymethamphetamine (MDMA) is an amphetamine analogue that preferentially stimulates the release of serotonin (5HT) and results in relatively small increases in synaptic dopamine (DA). The ratio of drug‐stimulated increases in synaptic DA, relative to 5HT, predicts the abuse liability; drugs with higher DA:5HT ratios are more likely to be abused. Nonetheless, MDMA is a drug...

Free energy calculations of the functional selectivity of 5-HT2B G protein-coupled receptor.

PLoS One March 4, 2021 Brandon L Peters, Jinxia Deng, Andrew L Ferguson 4 citations

G Protein-Coupled Receptors (GPCRs) mediate intracellular signaling in response to extracellular ligand binding and are the target of one-third of approved drugs. Ligand binding modulates the GPCR molecular free energy landscape by preferentially stabilizing active or inactive conformations that dictate intracellular protein recruitment and downstream signaling. We perform enhanced sampling...

Serotonin 2A Receptor (5-HT2AR) Activation by 25H-NBOMe Positional Isomers: In Vitro Functional Evaluation and Molecular Docking.

ACS Pharmacology & Translational Science February 25, 2021 Eline Pottie, Olga V. Kupriyanova, Asher L. Brandt et al.

Serotonergic psychedelics are defined as compounds having serotonin 2A receptor (5-HT2AR) activation as an important pharmacological mechanism. These compounds include the phenylalkylamine class, containing substances with e.g. 2C-X structures (phenethylamines) or their N-methoxybenzyl analogues (NBOMes). Besides their abuse potential, psychedelics are increasingly recognized for having...

Increased kynurenine concentration attenuates serotonergic neurotoxicity induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats through activation of aryl hydrocarbon receptor.

Neuropharmacology February 16, 2021 C. Abuin-Martínez, Rebeca Vidal, Maria D Gutierrez-Lopez et al.

3,4-Methylenedioxymethamphetamine (MDMA) is an amphetamine derivative that has been shown to produce serotonergic damage in the brains of primates, including humans, and of rats. Tryptophan, the precursor of serotonin, is primarily degraded through the kynurenine (KYN) pathway, producing among others KYN, the main metabolite of this route. KYN has been reported as an endogenous agonist of the...